Showing 1 - 6 results of 6 for search 'G. J. Robbrecht', query time: 0.03s Refine Results
  1. 1
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial by V. C. Rutten, Y. Salhi, G. J. Robbrecht, R. de Wit, G. J.L.H. van Leenders, T. C.M. Zuiverloon, J. L. Boormans

    Published 2023-06-01
    Get full text
    Article
  2. 2
    Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

    Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort by Anke Richters, Debbie G.J. Robbrecht, Richard P. Meijer, Antoine G. van der Heijden, Lambertus A.L.M. Kiemeney, Joan van den Bosch, Britt B.M. Suelmann, Berna C. Özdemir, Niven Mehra, Katja K.H. Aben

    Published 2024-01-01
    Get full text
    Article
  3. 3
    ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

    ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study by Marit A. C. Vermunt, Debbie G. J. Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten vanEijk, Rob Kessels, Ferry A. L. M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman

    Published 2021-08-01
    Get full text
    Article
  4. 4
    Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

    Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE tr... by C.F. Stockem, J.J.J. Mellema, B.W.G. van Rhijn, T.N. Boellaard, M.L. van Montfoort, S. Balduzzi, J.L. Boormans, M. Franckena, R.P. Meijer, D.G.J. Robbrecht, B.B.M. Suelmann, E.E. Schaake, M.S. van der Heijden

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

    Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer by Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, Maud Rijnders, Ronald deWit, Vanja deWeerd, Teoman Deger, Hans M. Westgeest, Maureen J. B. Aarts, Jens Voortman, John W. M. Martens, Astrid A. M. van derVeldt, José Alberto Nakauma‐González, Saskia M. Wilting, Martijn Lolkema

    Published 2022-05-01
    Get full text
    Article
  6. 6
    Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer

    Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer by Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema

    Published 2024-02-01
    Get full text
    Article

Search Tools: